Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...
Blueprint's Albers hands CEO baton to deal mastermind Haviland after steering 2 cancer drug launches
When Jeff Albers joined Blueprint Medicines in 2014, the private company was a clinical-stage biotech. Now, the helmsman is handing down the reins after steering the firm through an IPO and two drug ...
Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has three ...
Realizing not everyone has the time to consume endless content on club launch day, we’re offering a fresh version of our detailed tech write-ups that hits on the high points. Here’s what you need to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results